Endogenous Hypercortisolemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for endogenous hypercortisolemia. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
5
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators in Endogenous Hypercortisolemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Strongbridge 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating endogenous hypercortisolemia. Each bar = one year. Y-axis scaled to peak year (4 patents).

1
28
4
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Recorlev
LEVOKETOCONAZOLE
 Strongbridge 5 57 — 2028-05-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9918984 Recorlev method of use 66 2028-05-03
12377096 Recorlev method of use 58 2040-03-02
11903940 Recorlev method of use 58 2040-03-02
11020393 Recorlev method of use 53 2040-03-02
11278547 Recorlev method of use 53 2040-03-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11020393 Recorlev method of use 53 2040-03-02
11278547 Recorlev method of use 53 2040-03-02
12377096 Recorlev method of use 58 2040-03-02
11903940 Recorlev method of use 58 2040-03-02
9918984 Recorlev method of use 66 2028-05-03

Related